Latest Conference Coverage


Thomas Leist, MD: Resetting the Immune System With Cladribine

Thomas Leist, MD: Resetting the Immune System With Cladribine

October 19th 2018

The director of the Comprehensive Multiple Sclerosis Center at Thomas Jefferson University discussed the concept of lymphocyte depletion to reset the immune system.


Teriflunomide Slows Brain Atrophy In Patients At Risk for MS Conversion

Teriflunomide Slows Brain Atrophy In Patients At Risk for MS Conversion

October 18th 2018

Results suggested that for every 1% of brain volume lost, a 51.7% increase in risk of clinically definite MS conversion was observed.


Peter Calabresi, MD: Clinically Validating Neurofilament Light

Peter Calabresi, MD: Clinically Validating Neurofilament Light

October 16th 2018

One of the highly debated topics at ECTRIMS 2018 was the use of the investigational biomarker, neurofilament light, in the clinic.


John Corboy, MD: The DISCO-MS Trial

John Corboy, MD: The DISCO-MS Trial

October 13th 2018

The professor of neurology at Colorado University spoke about the ongoing phase IV trial to determine the safety of DMT discontinuation in MS.


Cell Therapies Offer Hope But Are Often Misused

Cell Therapies Offer Hope But Are Often Misused

October 13th 2018

Cellular therapies have the potential to make a meaningful difference for patients with neurological disorders, if used correctly.


Fernando Dangond, MD, MBA: Evobrutinib for Relapsing Multiple Sclerosis

Fernando Dangond, MD, MBA: Evobrutinib for Relapsing Multiple Sclerosis

October 12th 2018

The Head of Global Clinical Development in Neurology at EMD Serono provided insight into the therapy's performance in phase IIb.


Thomas Leist, MD: Immune Reconstitution Therapy for Multiple Sclerosis

Thomas Leist, MD: Immune Reconstitution Therapy for Multiple Sclerosis

October 12th 2018

The director of Thomas Jefferson's Comprehensive Multiple Sclerosis Center spoke about the introduction of this treatment method into MS.


Robert J. Fox, MD: Neurofilament Light as a Biomarker of Treatment Response

Robert J. Fox, MD: Neurofilament Light as a Biomarker of Treatment Response

October 11th 2018

The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis spoke about the current understanding of the biomarker.


Hideki Garren, MD, PhD: The ORATORIO-HAND Trial in PPMS

Hideki Garren, MD, PhD: The ORATORIO-HAND Trial in PPMS

October 11th 2018

The Global Head of Neuroimmunology at Genentech discussed the upcoming phase III trial of ocrelizumab while on-site at ECTRIMS 2018.


Cladribine Tablets Safety Profile Reaffirmed With Long-Term Data

Cladribine Tablets Safety Profile Reaffirmed With Long-Term Data

October 11th 2018

An updated safety analysis of the therapy in patients with relapsing MS, up to 10 years, has shown no new safety signals.


Richard Rudick, MD: Using Data to Personalize MS Care

Richard Rudick, MD: Using Data to Personalize MS Care

October 10th 2018

The vice president of Medical Research at Biogen spoke about the intersection between high-quality data utilization and individualized medicine in multiple sclerosis.


John Corboy, MD: Taking Patients Off Of Disease-Modifying Therapy

John Corboy, MD: Taking Patients Off Of Disease-Modifying Therapy

October 10th 2018

The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.


Earlier Treatment With Ocrelizumab Shows Favorable Results in Relapsing, Primary Progressive MS

Earlier Treatment With Ocrelizumab Shows Favorable Results in Relapsing, Primary Progressive MS

October 10th 2018

Data from multiple open-label extension trials have suggested that the therapy is more beneficial with earlier initiation compared to interferon ß-1a.


Eva Winnebeck, PhD: Temporal Dynamics of Sleep

Eva Winnebeck, PhD: Temporal Dynamics of Sleep

October 9th 2018

The postdoctoral scientist spoke about an actimetry-based method studying the clinical relevance of temporal dynamics of sleep to make the dynamics easily quantifiable in everyday context.


Johan Verbraecken, MD, PhD: Challenges in Conducting Clinical Trials in OSA

Johan Verbraecken, MD, PhD: Challenges in Conducting Clinical Trials in OSA

October 8th 2018

The medical coordinator of the Multidisciplinary Sleep-Wake Disorders Center at Antwerp University Hospital spoke about how to address some of the issues faced in OSA treatment development.


Tessa Blanken, MSc: Identification of Robust, Clinically Relevant Insomnia Subtypes

Tessa Blanken, MSc: Identification of Robust, Clinically Relevant Insomnia Subtypes

October 5th 2018

The identification of the subtypes allows future studies to target homogeneous subtype samples, resolve inconsistencies, personalize treatment and utilize preventive interventions.


Danny Eckert, PhD: Pharmacotherapies Reducing OSA Severity

Danny Eckert, PhD: Pharmacotherapies Reducing OSA Severity

October 4th 2018

Proof-of-concept studies using a targeted phenotypic approach to reduce obstructive sleep apnea severity are showing exciting results.


Danny Eckert, PhD: Unlocking New Targets For Pharmacological Therapy In OSA

Danny Eckert, PhD: Unlocking New Targets For Pharmacological Therapy In OSA

October 3rd 2018

The identification of 3 key non-anatomical contributors to OSA has unlocked new potential pharmacotherapies, a major advance for the field.


Jan Hedner, MD, PhD: Current Therapeutic Landscape of Obstructive Sleep Apnea

Jan Hedner, MD, PhD: Current Therapeutic Landscape of Obstructive Sleep Apnea

October 1st 2018

Recent research has identified novel potential pathophysiological mechanisms that could potentially serve to subclassify various phenotypes in obstructive sleep apnea.


Eva Winnebeck, PhD: Movement Rhythms During Sleep

Eva Winnebeck, PhD: Movement Rhythms During Sleep

October 1st 2018

The actimetry-based method allows for easily quantifiable sleep dynamics in real life context, enabling large-scale clinical studies to investigate the complex temporal dynamics of sleep.


Krista Lanctot, PhD: Managing Patients with Agitation

Krista Lanctot, PhD: Managing Patients with Agitation

September 30th 2018

Lanctôt advised ruling out any possible underlying medical conditions that could be causing it, including pain, as well as starting with any non-pharmacologic interventions.

© 2024 MJH Life Sciences

All rights reserved.